National Institute of Mental Health (NIMH)

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, National Institute of Mental Health (NIMH) sits in the top decile of US sponsors by registered trial count (#103 of 15,742 sponsors by registered trial count).

343 total trials 42 currently recruiting 256 completed early-phase tilt top decile by trial count

National Institute of Mental Health (NIMH): 343 sponsored US clinical trials, 42 recruiting.

National Institute of Mental Health (NIMH) sponsors 343 registered US clinical trials on ClinicalTrials.gov, 42 of them currently recruiting, and 256 completed. 29 of these trials are in Phase 3-4 (later-stage) and 106 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Healthy, with 21 trials.

Top-decile sponsor footprint

National Institute of Mental Health (NIMH) ranks in the top decile of sponsors by registered trial count (#103 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

D 56/100

256 of 296 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (86.5%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

343 total, page 3 of 7

TERMINATED

Oxytocin and Arginine Vasopressin in Pain Relief

NCT01328561

TERMINATED

A Study of the Association Between Autism and Immune Changes in the Brain

NCT01322555

COMPLETED Phase 3

Intravenous Immunoglobulin for PANDAS

NCT01281969

COMPLETED Early Phase 1

PET Brain and Whole Body Distribution Studies for Nociceptin/Orphanin FQ Peptide (NOP) Receptor Using [11C]NOP-1A

NCT01198197

COMPLETED

An Exploratory Study of the Characteristics of and Challenges for International Families Seeking Medical Care in the United States

NCT01211990

COMPLETED

PET Whole Body Distribution Studies Using [11C]CUMI

NCT01132872

COMPLETED

Cognitive Neuroscience of Autism Spectrum Disorders

NCT01031407

COMPLETED Phase 1

Brain Imaging Study of Adults With Autism Spectrum Disorders

NCT01093768

TERMINATED

Imaging Cannabinoid CB1 Receptors in Schizophrenia

NCT01063335

COMPLETED

Effects of a CRF1 Receptor Antagonist on Human Startle in Normal Female Volunteers

NCT01059227

TERMINATED

A Magnetic Resonance Spectroscopic Examination of Children and Adolescents Taking Riluzole for Obsessive-Compulsive Disorder

NCT01019967

COMPLETED

Functional Relevance of Dopamine Receptors in Healthy Controls and Patients With Schizophrenia: Characterization Through [11C]NNC-112 and [18F]Fallypride Positron Emission Tomography

NCT00942981

COMPLETED

Characterizing Lone Parenting: A Multi-institutional Pilot Study of the Perceptions of Support and Perceived Stress of Lone Parents of Children With Cancer

NCT00969579

COMPLETED

Screening and Evaluation of Patients With Signs and Symptoms of Alzheimer's Disease

NCT00955422

COMPLETED Phase 4

Feasibility of Providing Cognitive Remediation to People With Schizophrenia in a Clinical Network

NCT00930150

TERMINATED

CO2 Inhalation and Risk for Panic Disorder

NCT00930657

COMPLETED

Identification of Characteristics Associated With Symptom Remission in Autism

NCT00938054

COMPLETED

Regional Rates of Cerebral Protein Synthesis: Effects of Sleep and Memory Consolidation

NCT00884702

COMPLETED

Development and Decline of Brain and Cognition Through the Life Span

NCT00880451

COMPLETED

The Use of a Distress Thermometer in a Pediatric Research Setting: An Exploratory Pilot Study

NCT00824278

COMPLETED Phase 4

The Use of Metformin in the Treatment of Antipsychotic-Induced Weight Gain in Schizophrenia (The METS Study)

NCT00816907

COMPLETED

Imaging Cannabinoid CB1 Receptors in Alcohol Dependence

NCT00816439

COMPLETED Phase 4

Comparison of Optimal Antipsychotic Treatments for Adults With Schizophrenia

NCT00802100

COMPLETED Phase 2

A Controlled Trial of Serotonin Reuptake Inhibitors Added to Stimulant Medication in Youth With Severe Mood Dysregulation

NCT00794040

TERMINATED Phase 2

Double-Blind Placebo-Controlled Trial of Riluzole in Pediatric Bipolar Disorder

NCT00805493

TERMINATED Phase 1

Transcranial Direct Current Brain Stimulation to Treat Patients With Childhood-Onset Schizophrenia

NCT00757497

COMPLETED

PET Imaging of Peripheral Benzodiazepine Receptors

NCT00696371

COMPLETED

p11 Protein Levels in Patients With Major Depressive Disorder Treated With Citalopram

NCT00697268

COMPLETED Phase 1

The Effect of Donepezil (Aricept(Registered Trademark)) on REM Sleep in Children With Autism

NCT00695136

COMPLETED

P-glycoprotein Function in Brain Diseases

NCT00677885

COMPLETED Phase 4

Effectiveness of Lithium Plus Optimized Medication in Treating People With Bipolar Disorder

NCT00667745

COMPLETED

Mirror Therapy for Phantom Limb Pain

NCT00623818

COMPLETED Phase 4

Combining Medications to Enhance Depression Outcomes

NCT00590863

COMPLETED

Detecting Risk of Suicide in a Pediatric Emergency Department

NCT00623493

COMPLETED

PET Evaluation of Brain Peripheral Benzodiazepine Receptors Using [11C]PBR28 in Frontotemporal Dementia

NCT00613119

COMPLETED

PET Imaging of P-glycoprotein Function Using [11C]dLop

NCT00605254

COMPLETED Phase 1

PET Imaging of Cannabinoid CB1 Receptors Using [11C]MePPEP

NCT00598390

COMPLETED Phase 1

PET Imaging of Cannabinoid CB1 Receptors Using [18F]FMPEP-d2

NCT00598286

COMPLETED Phase 1

PET Imaging of Peripheral Benzodiazepine Receptors in Patients With Carotid Atherosclerosis

NCT00547976

TERMINATED Phase 2

The Effects of Atomoxetine on Cognition and Brain Function Based on Catechol-O-methyltransferase(COMT) Genotype

NCT00548327

COMPLETED Phase 1

PET Imaging of Brain mGluR5 Receptors Using [18F]SP203

NCT00538798

COMPLETED Phase 1

PET Imaging of Peripheral Benzodiazepine Receptors in Patients With Neurocysticercosis Using [F-18]FB

NCT00527579

COMPLETED Phase 1

PET Imaging of Peripheral Benzodiazepine Receptors in Patients With Neurocysticercosis Using [C-11]PBR28

NCT00526916

COMPLETED

Assessing Treatment Emergent Suicidal Ideation in Patients With Major Depression

NCT00532103

COMPLETED Phase 1

Antidepressant Effects of NR2B in Major Depression

NCT00472576

TERMINATED NA

PET Evaluation of Brain Peripheral Benzodiazepine Receptors Using [11C]PBR28 in HIV-Seropositive Patients With (MCMD)

NCT00459693

COMPLETED

Functional Neuroanatomy of Emotion Perception, Recognition, Learning, and Memory

NCT00458432

COMPLETED Phase 1

Imaging of Cannabinoid Receptors Using New Radioactive Tracer

NCT00450021

COMPLETED Phase 4

Comparison of Antipsychotics for Metabolic Problems in Schizophrenia or Schizoaffective Disorder

NCT00423878

COMPLETED Phase 1

PET Imaging of Brain Amyloid Using [11C]MeS-IMPY

NCT00407576

← Previous Page 3 of 7 Next →

Phase Distribution

PhaseTrial count
Phase 1 61
Phase 2 45
Phase 3 8
Phase 4 21

What is open in the National Institute of Mental Health (NIMH) pipeline

42 recruiting of 343 indexed (12% open); 256 completed (75%).

Phase mix: 29 late (III/IV) vs 106 early (I/II) (early-phase heavy).

Top condition: Healthy (21 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

National Institute of Mental Health (NIMH): open-pipeline peers nationwide

Peers matched on 343 registered trials and 12% open enrollment, not the therapeutic-area sidebar.

National Institute of Mental Health (NIMH) sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 0100200300400 5%10%15%20%25% Total trials Recruiting share National Institute of Mental Health (NIMH)Children's Oncology GroupMontefiore Medical CenterOhio State University Comprehensive Cancer CenterCedars-Sinai Medical CenterAugusta UniversityUniversity of IowaDaiichi SankyoFriends Research Institute
National Institute of Mental Health (NIMH) sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

National Institute of Mental Health (NIMH) sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 343 trials (± recruiting share)

Sponsors near 12% open enrollment (± trial volume)

What to do with this National Institute of Mental Health (NIMH) page

343 registered trials is a research-attention snapshot, not an endorsement of National Institute of Mental Health (NIMH) or any single study.

  • 42 of National Institute of Mental Health (NIMH)'s trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Healthy is the condition National Institute of Mental Health (NIMH) studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Healthy trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

National Institute of Mental Health (NIMH) pipeline card: 343 registered trials from official public datasets.Report a data error.